Emad Alatassi, MD
Sleep Medicine · Roseville, MINPI 1528018256
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 430 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by GSK at 30.9% of the total. Among sleep medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Sanofi$786
- Jazz Pharmaceuticals Inc.$623
- Regeneron Healthcare Solutions, Inc.$450
- Mylan Specialty L.p.$279
- plus $2K from 28 others
What the payments were for
- Food & beverage$8,65998%
- Education$1572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 167 | $2,727 |
| AstraZeneca | 67 | $1,621 |
| Sanofi | 33 | $786 |
| Jazz Pharmaceuticals Inc. | 19 | $623 |
| Regeneron Healthcare Solutions, Inc. | 21 | $450 |
| Mylan Specialty L.p. | 11 | $279 |
| Boehringer Ingelheim | 13 | $259 |
| Harmony Biosciences LLC | 11 | $239 |
| Actelion Pharmaceuticals US, Inc. | 9 | $230 |
| Sanofi-aventis U.S. LLC | 2 | $157 |
| Resmed Corp | 7 | $145 |
| Pulmonx Corporation | 5 | $126 |
| Inspire Medical Systems, Inc. | 1 | $123 |
| Azurity Pharmaceuticals, Inc. | 6 | $107 |
| Grifols USA, LLC | 6 | $104 |
| Verona Pharma, Inc. | 5 | $100 |
| Insmed, Inc. | 5 | $91 |
| Sunovion Pharmaceuticals Inc. | 12 | $90 |
| Viatris Specialty LLC | 4 | $87 |
| Inogen, Inc. | 6 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Baxter Healthcare | 1 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Gilead | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Electromed, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,816 in reported general payments places this provider in the 90th percentile of 78 sleep medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 237 | $186,793 |
| NucalaMepolizumab | 24 | $87,219 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $49,856 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $25,163 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $20,035 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $13,193 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,759 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 231 | $7,715 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $7,368 |
| Ventolin HfaAlbuterol Sulfate | 89 | $5,433 |
| VascepaIcosapent Ethyl | 11 | $3,538 |
| Modafinil | 26 | $1,792 |
| Ipratropium Bromide | 20 | $791 |
| Eszopiclone | 11 | $611 |
| Fluticasone Propionate | 51 | $486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $2,727 | $349,031425 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $259 | $23,95232 claims |
| AstraZenecaBreztri Aerosphere | $1,621 | $20,03532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 78 sleep medicine providers in Michigan.
Other sleep medicine in Roseville
- Vishal PatelRoyal Oak$507K
- Vishal SainiSaginaw$176K
- Oktai MamedovEast Lansing$62K
- Nathan BossCharlevoix$43K
- Kelly WatersGrand Rapids$30K
- Abdul MalikTraverse City$12K
- Albert HoGrand Rapids$10K
- Zachary RichensPortage$6K
- Michel AlkhalilTroy$6K
- Alice DoeKalamazoo$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.